New radioactive beads aim to outperform standard liver cancer therapy
NCT ID NCT06900543
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. The main goal is to see which treatment delays cancer growth longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NRT6003 injection (yttrium-90 carbon microspheres)
What this could lead to
If it works, this could offer a more effective, targeted treatment option for people with liver cancer that cannot be surgically removed.
What could go wrong
This is a Phase 3 trial, but it is still early to know if NRT6003 is truly better than the standard treatment. The study is small (108 people) and only in Chinese patients, so results may not apply to everyone. Risks include radiation exposure and liver damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
-
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
-
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
-
The First Hospital Affiliated to the Army Medical University
Chongqing, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
-
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital
Chengdu, Sichuan, China
-
Xi'an International Medical Center Hospital
Xi’an, Shanxi, China
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, 210009, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
-
Zhongshan Hospital Fudan University
Shanghai, China